Cingulate FDA Rejection of ADHD Drug Signals Near-Term Stock Pressure
FDA declined to approve Cingulate's lead ADHD therapy, marking a regulatory setback. The news removes an immediate catalyst and creates near-term downside as investors await clarity on reasons for denial, required follow-up steps, and potential funding or strategic options to advance the program.
View signal analysis